Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01735331|
Recruitment Status : Completed
First Posted : November 28, 2012
Last Update Posted : August 7, 2015
|Condition or disease|
|Recurrent Pregnancy Loss Without Current Pregnancy|
This study is a prospective,observational,single-center study.Ethical approval was obtained from the Institutional Review Board.This study will be completed 30 patients with Habitual Abortus.
Endometrial vascular endothelial growth factor levels will be measured using Flk-1 / Kinase Domain Receptor / Vascular endothelial growth factor receptor-2, Ab-1 (Rabbit PAb), Vascular Endothelial Growth Factor (VEGF) Ab-7 (VG1), Cluster of Differentiation 34 (Endothelial Cell Marker) Ab-1 (QBEnd/10), Vascular endothelial growth factor receptor-1 (N-term) (FLT1) antibody kits. All assays will be performed according to the manufacturer's instructions.
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Observational Model:||Case Control|
|Official Title:||Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
Patients with Abnormal Uterine Bleeding
- The primary outcome measure of this study is to determine endometrial vascular endothelial growth factor levels in patient with Recurrent Pregnancy Loss [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01735331
|Bagcilar Training and Research Hospital|
|Principal Investigator:||TANER A. USTA, M.D.||Bagcilar Training and Research Hospital,Istanbul,Turkey.|